


PreventionGenetics Acquired by Exact Sciences to Enable Earlier Cancer Detection and Hereditary Cancer Testing



During the past two decades since publication of the first draft of the human genome project, the use of genotyping and genomic testing has become integral to many cancer treatments, enabling more personalized or precision therapies. Today, precision medicine has grown into one of the highest growth market segments of the healthcare industry, valued at ~\$60 billion and projected to grow to ~\$100 billion **over the next five years**. As the market for precision medicine has grown, so, too has the need for genomic and genetic testing to support clinical decision-making.

With a goal to improve lives through genetic testing, PreventionGenetics offers more than 5,000 predefined genetic tests for nearly all clinically relevant genes, additional custom panels, and comprehensive germline whole

exome and whole genome sequencing tests. The Company's portfolio of tests for proactive health and wellness, cancer risk and screening, pediatric and adult-onset rare diseases, and others made PreventionGenetics the perfect complement to Exact Sciences' advanced cancer diagnostics portfolio and foundation to accelerate hereditary cancer testing (HCT).

Crosstree's deep expertise and successful track record in precision medicine helped PreventionGenetics evaluate a diverse range of potential strategic partners and identify Exact Sciences as an ideal fit from both economic and cultural perspectives. The resulting acquisition will enable PreventionGenetics to continue its growth trajectory and provide a strong strategic complement to Exact Sciences' existing capabilities.

Crosstree helps clients identify the optimal transaction partners to enhance value for all stakeholders.

ABOUT PREVENTIONGENETICS



Founded in 2004 and located in Marshfield, Wisconsin, PreventionGenetics is a CLIA and ISO 15189:2012 accredited laboratory. PreventionGenetics delivers clinical genetic testing of the highest quality at fair prices with exemplary service to people around the world. PreventionGenetics has 25 PhD geneticists on staff and provides tests for nearly all clinically relevant genes including the powerful and comprehensive germline whole genome sequencing test, PGnome® and whole exome sequencing test, PGxome®.

ABOUT EXACT SCIENCES

EXACT SCIENCES

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.

CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER — BY THE NUMBERS AND BEYOND — IS CROSSTREE'S SPECIALTY.

Crosstree's **proven track record** of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



JEFF ELLIS, CFA

Co-Founder & Managing Director

jeff.ellis@crosstreecapital.com
813-774-4753